Cryptococcus: From environmental saprophyte to global pathogen

Nature Reviews Microbiology

Volumn 14, Issue 2, 2016, Pages 106-117

  May, Robin C ^a   Stone, Neil R H ^b   Wiesner, Darin L ^c   Bicanic, Tihana ^b   Nielsen, Kirsten ^c  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY OF LONDON   (United Kingdom)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT;

CRYPTOCOCCOSIS; FILOBASIDIELLA; GROWTH, DEVELOPMENT AND AGING; HOST PATHOGEN INTERACTION; HUMAN; IMMUNOLOGY; PATHOGENICITY; VIRULENCE;

ANTIFUNGAL AGENTS; CRYPTOCOCCOSIS; CRYPTOCOCCUS; HOST-PATHOGEN INTERACTIONS; HUMANS; VIRULENCE;

EID: 84955204640     PISSN: 17401526     EISSN: 17401534     Source Type: Journal    
DOI: 10.1038/nrmicro.2015.6     Document Type: Review

References (138)

1. Kwon-Chung, J. K., Boekhout, T., Fell, J. W., Diaz, M. Proposal to conserve the name Cryptococcus gattii against C. hondurianus and C. basillisporus (Basidiomycota, Hymenomycetes, Tremellomycetidae). Taxon 51, 804-806 (2002).
2. Hagen, F. et al. Recognition of seven species in the Cryptococcus gattii/Cryptococcus neoformans species complex. Fungal Genet. Biol. 78, 16-48 (2015).
3. Springer, D. J. et al. Cryptococcus gattii VGIII isolates causing infections in HIV/AIDS patients in Southern California: identification of the local environmental source as arboreal. PLoS Pathog. 10, e1004285 (2014).
4. Chowdhary, A., Rhandhawa, H. S., Prakash, A., Meis, J. F. Environmental prevalence of Cryptococcus neoformans and Cryptococcus gattii in India: an update. Crit. Rev. Microbiol. 38, 1-16 (2012).
5. Litvintseva, A. P. et al. Evidence that the human pathogenic fungus Cryptococcus neoformans var. grubii may have evolved in Africa. PLoS ONE 6, e19688 (2011).
6. Baddley, J. W. et al. Transmission of Cryptococcus neoformans by organ transplantation. Clin. Infect. Dis. 52, e94-e98 (2011).
7. Lagrou, K. et al. Zoonotic transmission of Cryptococcus neoformans from a magpie to an immunocompetent patient. J. Intern. Med. 257, 385-388 (2005).
8. Goldman, D. L. et al. Serologic evidence for Cryptococcus neoformans infection in early childhood. Pediatrics 107, E66 (2001).
9. Giles, S. S., Dagenais, T. R., Botts, M. R., Keller, N. P., Hull, C. M. Elucidating the pathogenesis of spores from the human fungal pathogen Cryptococcus neoformans. Infect. Immun. 77, 3491-3500 (2009).
10. Springer, D. J., Saini, D., Byrnes, E. J., Heitman, J., Frothingham, R. Development of an aerosol model of Cryptococcus reveals humidity as an important factor affecting the viability of Cryptococcus during aerosolization. PLoS ONE 8, e69804 (2013).
11. Velagapudi, R., Hsueh, Y. P., Geunes-Boyer, S., Wright, J. R., Heitman, J. Spores as infectious propagules of Cryptococcus neoformans. Infect. Immun. 77, 4345-4355 (2009).
12. Zaragoza, O. et al. The capsule of the fungal pathogen Cryptococcus neoformans. Adv. Appl. Microbiol. 68, 133-216 (2009).
13. McDonald, T., Wiesner, D. L., Nielsen, K. Cryptococcus. Curr. Biol. 22, R554-R555 (2012).
14. Zaragoza, O., Nielsen, K. Titan cells in Cryptococcus neoformans: cells with a giant impact. Curr. Opin. Microbiol. 16, 409-413 (2013).
15. Okagaki, L. H. et al. Cryptococcal cell morphology affects host cell interactions and pathogenicity. PLoS Pathog. 6, e1000953 (2010).
16. Zaragoza, O. et al. Fungal cell gigantism during mammalian infection. PLoS Pathog. 6, e1000945 (2010).
17. Wiesner, D. L. et al. Chitin recognition via chitotriosidase promotes pathologic type-2 helper T cell responses to cryptococcal Infection. PLoS Pathog. 11, e1004701 (2015).
18. Gerstein, A. C. et al. Polyploid titan cells produce haploid and aneuploid progeny to promote stress adaptation. mBio 6, e01340-01415 (2015).
19. Alanio, A., Vernel-Pauillac, F., Sturny-Lecle, A., Dromer, F. Cryptococcus neoformans host adaptation: toward biological evidence of dormancy. mBio 6, e02580-e02614 (2015).
20. Feldmesser, M., Kress, Y., Casadevall, A. Dynamic changes in the morphology of Cryptococcus neoformans during murine pulmonary infection. Microbiology 147, 2355-2365 (2001).
21. Neilson, J. B., Fromtling, R. A., Bulmer, G. S. Pseudohyphal forms of Cryptococcus neoformans: decreased survival in vivo. Mycopathologia 73, 57-59 (1981).
22. Wang, L., Zhai, B., Lin, X. The link between morphotype transition and virulence in Cryptococcus neoformans. PLoS Pathog. 8, e1002765 (2012).
23. Magditch, D. A., Liu, T. B., Xue, C., Idnurm, A. DNA mutations mediate microevolution between host-adapted forms of the pathogenic fungus Cryptococcus neoformans. PLoS Pathog. 8, e1002936 (2012).
24. Lin, J., Idnurm, A., Lin, X. Morphology and its underlying genetic regulation impact the interaction between Cryptococcus neoformans and its hosts. Med. Mycol. 53, 493-504 (2015).
25. Bouklas, T., Fries, B. C. Aging as an emergent factor that contributes to phenotypic variation in Cryptococcus neoformans. Fungal Genet. Biol. 78, 59-64 (2014).
26. Bouklas, T. et al. Old Cryptococcus neoformans cells contribute to virulence in chronic cryptococcosis. mBio 4, e00455-00413 (2013).
27. Jain, N. et al. Isolation and characterization of senescent C. neoformans and its implications for phenotypic switching and the pathogenesis of chronic cryptococcosis. Eukaryot. Cell 8, 858-866 (2009).
28. Lee, H., Chang, Y. C., Nardone, G., Kwon-Chung, K. J. TUP1 disruption in Cryptococcus neoformans uncovers a peptide-mediated density-dependent growth phenomenon that mimics quorum sensing. Mol. Microbiol. 64, 591-601 (2007).
29. Albuquerque, P. et al. Quorum sensing-mediated, cell density-dependent regulation of growth and virulence in Cryptococcus neoformans. mBio 5, e00986-e00913 (2014).
30. Wang, L., Tian, X., Gyawali, R., Lin, X. Fungal adhesion protein guides community behaviors and autoinduction in a paracrine manner. Proc. Natl Acad. Sci. USA 110, 11571-11576 (2013).
31. Albuquerque, P. C. et al. Cryptococcus neoformans glucuronoxylomannan fractions of different molecular masses are functionally distinct. Future Microbiol. 9, 147-161 (2014).
32. Idnurm, A., Heitman, J. Light controls growth and development via a conserved pathway in the fungal kingdom. PLoS Biol. 3, e95 (2005).
33. Schoffelen, T. et al. Cryptococcus gattii induces a cytokine pattern that is distinct from other cryptococcal species. PLoS ONE 8, e55579 (2013).
34. Piccioni, M. et al. A purified capsular polysaccharide markedly inhibits inflammatory response during endotoxic shock. Infect. Immun. 81, 90-98 (2013).
35. Angkasekwinai, P. et al. Cryptococcus gattii infection dampens Th1 and Th17 responses by attenuating dendritic cell function and pulmonary chemokine expression in the immunocompetent hosts. Infect. Immun. 82, 3880-3890 (2014).
36. Qiu, Y. et al. Immune modulation mediated by cryptococcal laccase promotes pulmonary growth and brain dissemination of virulent Cryptococcus neoformans in mice. PLoS ONE 7, e47853 (2012).
37. Davis, M. J. et al. Macrophage M1/M2 polarization dynamically adapts to changes in cytokine microenvironments in Cryptococcus neoformans infection. mBio 4, e00264-e00213 (2013).
38. Voelz, K., Lammas, D. A., May, R. C. Cytokine signaling regulates the outcome of intracellular macrophage parasitism by Cryptococcus neoformans. Infect. Immun. 77, 3450-3457 (2009).
39. Muller, U. et al. Abrogation of IL-4 receptor-dependent alternatively activated macrophages is sufficient to confer resistance against pulmonary cryptococcosis despite an ongoing Th2 response. Int. Immunol. 25, 459-470 (2013).
40. Hardison, S. E. et al. Protective immunity against pulmonary cryptococcosis is associated with STAT1-mediated classical macrophage activation. J. Immunol. 189, 4060-4068 (2012).
41. Flaczyk, A. et al. IL-33 signaling regulates innate and adaptive immunity to Cryptococcus neoformans. J. Immunol. 191, 2503-2513 (2013).
42. Chen, G. H. et al. Inheritance of immune polarization patterns is linked to resistance versus susceptibility to Cryptococcus neoformans in a mouse model. Infect. Immun. 76, 2379-2391 (2008).
43. Coelho, C., Bocca, A. L., Casadevall, A. The intracellular life of Cryptococcus neoformans. Annu. Rev. Pathol. 9, 219-238 (2014).
44. Alvarez, M., Casadevall, A. Cell-to-cell spread and massive vacuole formation after Cryptococcus neoformans infection of murine macrophages. BMC Immunol. 8, 16 (2007).
45. Ma, H., Croudace, J. E., Lammas, D. A., May, R. C. Direct cell-to-cell spread of a pathogenic yeast. BMC Immunol. 8, 15 (2007).
46. Ma, H., Croudace, J. E., Lammas, D. A., May, R. C. Expulsion of live pathogenic yeast by macrophages. Curr. Biol. 16, 2156-2160 (2006).
47. Alvarez, M., Casadevall, A. Phagosome extrusion and host-cell survival after Cryptococcus neoformans phagocytosis by macrophages. Curr. Biol. 16, 2161-2165 (2006).
48. Nicola, A. M., Robertson, E. J., Albuquerque, P., Derengowski Lda, S., Casadevall, A. Nonlytic exocytosis of Cryptococcus neoformans from macrophages occurs in vivo and is influenced by phagosomal pH. mBio 2, e00167-e00111 (2011).
49. Okagaki, L. H., Nielsen, K. Titan cells confer protection from phagocytosis in Cryptococcus neoformans infections. Eukaryot. Cell 11, 820-826 (2012).
50. Smith, L. M., Dixon, E. F., May, R. C. The fungal pathogen Cryptococcus neoformans manipulates macrophage phagosome maturation. Cell. Microbiol. (2014).
51. Davis, M. J. et al. Cryptococcus neoformans-induced macrophage lysosome damage crucially contributes to fungal virulence. J. Immunol. 194, 2219-2231 (2015).
52. Johnston, S. A., May, R. C. The human fungal pathogen Cryptococcus neoformans escapes macrophages by a phagosome emptying mechanism that is inhibited by Arp2/3 complex-mediated actin polymerisation. PLoS Pathog. 6, e1001041 (2010).
53. Erb-Downward, J. R., Noggle, R. M., Williamson, P. R., Huffnagle, G. B. The role of laccase in prostaglandin production by Cryptococcus neoformans. Mol. Microbiol. 68, 1428-1437 (2008).
54. Evans, R. J. et al. Cryptococcal phospholipase B1 is required for intracellular proliferation and control of titan cell morphology during macrophage infection. Infect. Immun. 83, 1296-1304 (2015).
55. Vu, K. et al. Invasion of the central nervous system by Cryptococcus neoformans requires a secreted fungal metalloprotease. mBio 5, e01101-e01114 (2014).
56. Shi, M. et al. Real-time imaging of trapping and urease-dependent transmigration of Cryptococcus neoformans in mouse brain. J. Clin. Invest. 120, 1683-1693 (2010).
57. Olszewski, M. A. et al. Urease expression by Cryptococcus neoformans promotes microvascular sequestration, thereby enhancing central nervous system invasion. Am. J. Pathol. 164, 1761-1771 (2004).
58. Chang, Y. C. et al. Cryptococcal yeast cells invade the central nervous system via transcellular penetration of the blood-brain barrier. Infect. Immun. 72, 4985-4995 (2004).
59. Jong, A. et al. Involvement of human CD44 during Cryptococcus neoformans infection of brain microvascular endothelial cells. Cell. Microbiol. 10, 1313-1326 (2008).
60. Jong, A. et al. Invasion of Cryptococcus neoformans into human brain microvascular endothelial cells requires protein kinase C-activation. Cell. Microbiol. 10, 1854-1865 (2008).
61. Liu, T. B. et al. Brain inositol is a novel stimulator for promoting Cryptococcus penetration of the blood-brain barrier. PLoS Pathog. 9, e1003247 (2013).
62. Kechichian, T. B., Shea, J., Del Poeta, M. Depletion of alveolar macrophages decreases the dissemination of a glucosylceramide-deficient mutant of Cryptococcus neoformans in immunodeficient mice. Infect. Immun. 75, 4792-4798 (2007).
63. Charlier, C. et al. Evidence of a role for monocytes in dissemination and brain invasion by Cryptococcus neoformans. Infect. Immun. 77, 120-127 (2009).
64. Chen, Y. et al. The Cryptococcus neoformans transcriptome at the site of human meningitis. mBio 5, e01087-01013 (2014).
65. Robertson, E. J. et al. Cryptococcus neoformans ex vivo capsule size is associated with intracranial pressure and host immune response in HIV-associated cryptococcal meningitis. J. Infect. Dis. 209, 74-82 (2014).
66. Jarvis, J. N. et al. Cerebrospinal fluid cytokine profiles predict risk of early mortality and immune reconstitution inflammatory syndrome in HIV-associated cryptococcal meningitis. PLoS Pathog. 11, e1004754 (2015).
67. Datta, K. et al. Spread of Cryptococcus gattii into Pacific Northwest region of the United States. Emerg. Infect. Dis. 15, 1185-1191 (2009).
68. Harris, J. R. et al. Cryptococcus gattii in the United States: clinical aspects of infection with an emerging pathogen. Clin. Infect. Dis. 53, 1188-1195 (2011).
69. Ma, H. et al. The fatal fungal outbreak on Vancouver Island is characterized by enhanced intracellular parasitism driven by mitochondrial regulation. Proc. Natl Acad. Sci. USA 106, 12980-12985 (2009).
70. Voelz, K. et al. 'Division of labour' in response to host oxidative burst drives a fatal Cryptococcus gattii outbreak. Nat. Commun. 5, 5194 (2014).
71. Brizendine, K. D., Baddley, J. W., Pappas, P. G. Predictors of mortality and differences in clinical features among patients with cryptococcosis according to immune status. PLoS ONE 8, e60431 (2013).
72. Siddiqi, O. K. et al. Molecular diagnosis of central nervous system opportunistic infections in HIV-infected Zambian adults. Clin. Infect. Dis. 58, 1771-1777 (2014).
73. Anderson, T. M. et al. Amphotericin forms an extramembranous and fungicidal sterol sponge. Nat. Chem. Biol. 10, 400-406 (2014).
74. Belenky, P., Camacho, D., Collins, J. J. Fungicidal drugs induce a common oxidative-damage cellular death pathway. Cell Rep. 3, 350-358 (2013).
75. Gray, K. C. et al. Amphotericin primarily kills yeast by simply binding ergosterol. Proc. Natl Acad. Sci. USA 109, 2234-2239 (2012).
76. Brouwer, A. E. et al. Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. Lancet 363, 1764-1767 (2004).
77. Day, J. N. et al. Combination antifungal therapy for cryptococcal meningitis. N. Engl. J. Med. 368, 1291-1302 (2013).
78. Perfect, J. R. et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of America. Clin. Infect. Dis. 50, 291-322 (2010).
79. Loyse, A. et al. Cryptococcal meningitis: improving access to essential antifungal medicines in resource-poor countries. Lancet Infect. Dis. 13, 629-637 (2013).
80. ISRCTN Registry. A phase III, randomised, controlled trial for the treatment of HIV-associated cryptococcal meningitis: oral fluconazole plus flucytosine or one week amphotericin B-based therapy vs two weeks amphotericin B-based therapy. ISRCTN registry [online], http://dx.doi.org/10.1186/ISRCTN45035509 (2015).
81. Kelly, S. L. et al. Resistance to amphotericin B associated with defective sterol 87 isomerase in a Cryptococcus neoformans strain from an AIDS patient. FEMS Microbiol. Lett. 122, 39-42 (1994).
82. Bicanic, T., Harrison, T., Niepieklo, A., Dyakopu, N., Meintjes, G. Symptomatic relapse of HIV-associated cryptococcal meningitis after initial fluconazole monotherapy: the role of fluconazole resistance and immune reconstitution. Clin. Infect. Dis. 43, 1069-1073 (2006).
83. Sionov, E., Chang, Y. C., Garraffo, H. M., Kwon-Chung, K. J. Heteroresistance to fluconazole in Cryptococcus neoformans is intrinsic and associated with virulence. Antimicrob. Agents Chemother. 53, 2804-2815 (2009).
84. Sionov, E., Lee, H., Chang, Y. C., Kwon-Chung, K. J. Cryptococcus neoformans overcomes stress of azole drugs by formation of disomy in specific multiple chromosomes. PLoS Pathog. 6, e1000848 (2010).
85. Sionov, E., Chang, Y. C., Kwon-Chung, K. J. Azole heteroresistance in Cryptococcus neoformans: emergence of resistant clones with chromosomal disomy in the mouse brain during fluconazole treatment. Antimicrob. Agents Chemother. 57, 5127-5130 (2013).
86. Posteraro, B. et al. Identification and characterization of a Cryptococcus neoformans ATP binding cassette (ABC) transporter-encoding gene, CnAFR1, involved in the resistance to fluconazole. Mol. Microbiol. 47, 357-371 (2003).
87. Miyazaki, M. et al. In vitro activity of E1210, a novel antifungal, against clinically important yeasts and molds. Antimicrob. Agents Chemother. 55, 4652-4658 (2011).
88. Shibata, T. et al. T-2307 causes collapse of mitochondrial membrane potential in yeast. Antimicrob. Agents Chemother. 56, 5892-5897 (2012).
89. Brown, J. C. et al. Unraveling the biology of a fungal meningitis pathogen using chemical genetics. Cell 159, 1168-1187 (2014).
90. Dehdashti, S. J. et al. A high-throughput screening assay for assessing the viability of Cryptococcus neoformans under nutrient starvation conditions. Anal. Bioanal Chem. 405, 6823-6829 (2013).
91. Butts, A. et al. A repurposing approach identifies off-patent drugs with fungicidal cryptococcal activity, a common structural chemotype, and pharmacological properties relevant to the treatment of cryptococcosis. Eukaryot. Cell 12, 278-287 (2013).
92. Butts, A. et al. Estrogen receptor antagonists are anti-cryptococcal agents that directly bind EF hand proteins and synergize with fluconazole in vivo. mBio 5, e00765-e00713 (2014).
93. Zhai, B., Wu, C., Wang, L., Sachs, M. S., Lin, X. The antidepressant sertraline provides a promising therapeutic option for neurotropic cryptococcal infections. Antimicrob. Agents Chemother. 56, 3758-3766 (2012).
94. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01802385 (2015).
95. Saha, D. C. et al. Serologic evidence for reactivation of cryptococcosis in solid-organ transplant recipients. Clin. Vaccine Immunol. 14, 1550-1554 (2007).
96. Fang, W., Fa, Z., Liao, W. Epidemiology of Cryptococcus and cryptococcosis in China. Fungal Genet. Biol. 78, 7-15 (2014).
97. Beale, M. A. et al. Genotypic diversity is associated with clinical outcome and phenotype in cryptococcal meningitis across Southern Africa. PLoS Negl. Trop. Dis. 9, e0003847 (2015).
98. Litvintseva, A. P., Mitchell, T. G. Most environmental isolates of Cryptococcus neoformans var. grubii (serotype A) are not lethal for mice. Infect. Immun. 77, 3188-3195 (2009).
99. Wiesner, D. L. et al. Cryptococcal genotype influences immunologic response and human clinical outcome after meningitis. mBio 3, e00196-e00112 (2012).
100. Khayhan, K. et al. Geographically structured populations of Cryptococcus neoformans variety grubii in Asia correlate with HIV status and show a clonal population structure. PLoS ONE 8, e72222 (2013).
101. Ou, X. T. et al. Genotypes coding for mannose-binding lectin deficiency correlated with cryptococcal meningitis in HIV-uninfected Chinese patients. J. Infect. Dis. 203, 1686-1691 (2011).
102. Hu, X. P. et al. Association of Fc receptor IIB polymorphism with cryptococcal meningitis in HIV-uninfected Chinese patients. PLoS ONE 7, e42439 (2012).
103. Rohatgi, S. et al. Fc receptor 3A polymorphism and risk for HIV-associated cryptococcal disease. mBio 4, e00573-e00513 (2013).
104. Sabiiti, W. et al. Efficient phagocytosis and laccase activity affect the outcome of HIV-associated cryptococcosis. J. Clin. Invest. 124, 2000-2008 (2014).
105. Jarvis, J. N. et al. Evaluation of a novel point-of-care cryptococcal antigen test on serum, plasma, and urine from patients with HIV-associated cryptococcal meningitis. Clin. Infect. Dis. 53, 1019-1023 (2011).
106. Mfinanga, S. et al. Cryptococcal meningitis screening and community-based early adherence support in people with advanced HIV infection starting antiretroviral therapy in Tanzania and Zambia: an open-label, randomised controlled trial. Lancet 385, 60164-60167 (2015).
107. Findley, K. et al. Phylogeny and phenotypic characterization of pathogenic Cryptococcus species and closely related saprobic taxa in the Tremellales. Eukaryot. Cell 8, 353-361 (2009).
108. Xu, J., Vilgalys, R., Mitchell, T. G. Multiple gene genealogies reveal recent dispersion and hybridization in the human pathogenic fungus Cryptococcus neoformans. Mol. Ecol. 9, 1471-1481 (2000).
109. Litvintseva, A. P., Mitchell, T. G. Population genetic analyses reveal the African origin and strain variation of Cryptococcus neoformans var. grubii. PLoS Pathog. 8, e1002495 (2012).
110. Litvintseva, A. P., Lin, X., Templeton, I., Heitman, J., Mitchell, T. G. Many globally isolated AD hybrid strains of Cryptococcus neoformans originated in Africa. PLoS Pathog. 3, e114 (2007).
111. Billmyre, R. B. et al. Highly recombinant VGII Cryptococcus gattii population develops clonal outbreak clusters through both sexual macroevolution and asexual microevolution. mBio 5, e01494-e01414 (2014).
112. Hagen, F. et al. Ancient dispersal of the human fungal pathogen Cryptococcus gattii from the Amazon Rainforest. PLoS ONE 8, e71148 (2013).
113. Engelthaler, D. M. et al. Cryptococcus gattii in North American Pacific Northwest: whole-population genome analysis provides insights into species evolution and dispersal. mBio 5, e01464-e01414 (2014).
114. Fraser, J. A. et al. Same-sex mating and the origin of the Vancouver Island Cryptococcus gattii outbreak. Nature 437, 1360-1364 (2005).
115. Idnurm, A. et al. Deciphering the model pathogenic fungus Cryptococcus neoformans. Nat. Rev. Microbiol. 3, 753-764 (2005).
116. Lin, X., Hull, C. M., Heitman, J. Sexual reproduction between partners of the same mating type in Cryptococcus neoformans. Nature 434, 1017-1021 (2005).
117. Lin, X. et al. Diploids in the Cryptococcus neoformans serotype A population homozygous for the mating type originate via unisexual mating. PLoS Pathog. 5, e1000283 (2009).
118. Ni, M. et al. Unisexual and heterosexual meiotic reproduction generate aneuploidy and phenotypic diversity de novo in the yeast Cryptococcus neoformans. PLoS Biol. 11, e1001653 (2013).
119. Lin, X. et al. AD hybrids of Cryptococcus neoformans: evidence of same-sex mating in nature and hybrid fitness. PLoS Genet. 3, 1975-1990 (2007).
120. Bovers, M. et al. Unique hybrids between the fungal pathogens Cryptococcus neoformans and Cryptococcus gattii. FEMS Yeast Res. 6, 599-607 (2006).
121. Casadevall, A. Evolution of intracellular pathogens. Annu. Rev. Microbiol. 62, 19-33 (2008).
122. Wang, Y., Casadevall, A. Decreased susceptibility of melanized Cryptococcus neoformans to UV light. Appl. Environ. Microbiol. 60, 3864-3866 (1994).
123. Warpeha, K. M., Park, Y. D., Williamson, P. R. Susceptibility of intact germinating Arabidopsis thaliana to human fungal pathogens Cryptococcus neoformans and C. gattii. Appl. Environ. Microbiol. 79, 2979-2988 (2013).
124. Steenbergen, J. N., Shuman, H. A., Casadevall, A. Cryptococcus neoformans interactions with amoebae suggest an explanation for its virulence and intracellular pathogenic strategy in macrophages. Proc. Natl Acad. Sci. USA 98, 15245-15250 (2001).
125. Zaragoza, O. et al. Capsule enlargement in Cryptococcus neoformans confers resistance to oxidative stress suggesting a mechanism for intracellular survival. Cell. Microbiol. 10, 2043-2057 (2008).
126. Garcia-Hermoso, D., Janbon, G., Dromer, F. Epidemiological evidence for dormant Cryptococcus neoformans infection. J. Clin. Microbiol. 37, 3204-3209 (1999).
127. Kronstad, J. W. et al. Expanding fungal pathogenesis: Cryptococcus breaks out of the opportunistic box. Nat. Rev. Microbiol. 9, 193-203 (2011).
128. Steenbergen, J. N., Nosanchuk, J. D., Malliaris, S. D., Casadevall, A. Interaction of Blastomyces dermatitidis, Sporothrix schenckii, and Histoplasma capsulatum with Acanthamoeba castellanii. Infect. Immun. 72, 3478-3488 (2004).
129. Bliska, J. B., Casadevall, A. Intracellular pathogenic bacteria and fungi-a case of convergent evolution Nat. Rev. Microbiol. 7, 165-171 (2009).
130. Jarvis, J. N. et al. Adjunctive interferon-immunotherapy for the treatment of HIV-associated cryptococcal meningitis: a randomized controlled trial. AIDS 26, 1105-1113 (2012).
131. Saijo, T. et al. Anti-granulocyte-macrophage colony-stimulating factor autoantibodies are a risk factor for central nervous system infection by Cryptococcus gattii in otherwise immunocompetent patients. mBio 5, e00912-e00914 (2014).
132. Grahnert, A. et al. IL-4 receptor-dependent control of Cryptococcus neoformans in the early phase of pulmonary infection. PLoS ONE 9, e87341 (2014).
133. Schulze, B. et al. CD4+ FoxP3+ regulatory T cells suppress fatal T helper 2 cell immunity during pulmonary fungal infection. Eur. J. Immunol. 44, 3596-3604 (2014).
134. Murdock, B. J., Huffnagle, G. B., Olszewski, M. A., Osterholzer, J. J. Interleukin-17A enhances host defense against cryptococcal lung infection through effects mediated by leukocyte recruitment, activation, and interferon production. Infect. Immun. 82, 937-948 (2014).
135. Szymczak, W. A., Sellers, R. S., Pirofski, L. A. IL-23 dampens the allergic response to Cryptococcus neoformans through IL-17-independent and-dependent mechanisms. Am. J. Pathol. 180, 1547-1559 (2012).
136. Boulware, D. R. et al. Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis. N. Engl. J. Med. 370, 2487-2498 (2014).
137. Chang, C. C. et al. Cryptococcosis-IRIS is associated with lower cryptococcus-specific IFN-responses before antiretroviral therapy but not higher T-cell responses during therapy. J. Infect. Dis. 208, 898-906 (2013).
138. ISRCTN Registry. Adjunctive dexamethasone in HIV-infected adults with cryptococcal meningitis. ISRCTN registry [online], http://dx.doi.org/10.1186/ISRCTN59144167 (2015).